Patent ID: 8333965
Filing Date: 2012-12-18
Classification: A61K,A61P,C07K

Abstract:
1. A method for treating a disease or condition associated with increased expression of at least one IFNα protein subtype selected from the group consisting of protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA in a subject comprising administering to a subject having said disease or condition an effective amount of an antibody selected from the group consisting of: a) an anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557; b) a humanized antibody that is a humanized form of the anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557; c) a humanized antibody that is a humanized form of the antibody ACO-1; d) a humanized antibody that is an antibody fragment of a humanized form of the anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557, wherein the antibody fragment specifically neutralizes a bioactivity of at least ten interferon alpha protein subtypes selected from the group consisting of IFNα protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not significantly neutralize said bioactivity of IFNα protein subtype D, wherein said bioactivity is activation of the MxA promoter or antiviral activity; e) the humanized antibody of (d) that is an Fab, Fab′, F(ab′) f) an antibody comprising at least one light chain that comprises the CDRs: at least one heavy chain that comprises the CDRs: g) the antibody of any of (a) through (f) that is an IgG4 isotype antibody, wherein said disease or condition is selected from the group consisting of Systemic Lupus Erythematosus (SLE), type 1 diabetes, and psoriasis, and whereby at least one symptom of said disease or condition is treated or ameliorated.